X

Trial Profile

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of Nebulized IN-006 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regdanvimab (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man
Sponsors Inhalon Biopharma

Most Recent Events

07 Oct 2021 According to an Inhalon Biopharma media release, the study is being funded in part by a contract awarded by the U.S. Army Medical Research & Development Command (USAMRDC).
07 Oct 2021 According to an Inhalon Biopharma media release, the first patient has been dosed in the study.
07 Oct 2021 Status changed from not yet recruiting to recruiting, according to an Inhalon Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com